Effectiveness and Safety of Reduced-Dose Enoxaparin in Non–ST-Segment Elevation Acute Coronary Syndrome Followed by Antiplatelet Therapy Alone for Percutaneous Coronary Intervention
Authors:
- Scott J. DenardoSDScott J. Denardo
- Keith E. DavisKDKeith E. Davis
- James E. TchengJTJames E. Tcheng
- 1 November 2007
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 100 (9) , 1376-1382
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non–ST-Segment Elevation Acute Coronary SyndromesJAMA, 2005
- Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapyAmerican Heart Journal, 2005
- Eptifibatide provides additional platelet inhibition in Non–ST-Elevation myocardial infarction patients already treated with aspirin and clopidogrelJACC, 2004
- Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromesJACC, 2003
- Relation between the degree of procedural anticoagulation and complications after coronary stent implantationThe American Journal of Cardiology, 2003
- Redefining medical treatment in the management of unstable anginaThe American Journal of Medicine, 2000
- Heparin-Induced ThrombocytopeniaJACC, 1998
- Platelet Activation With Unfractionated Heparin at Therapeutic Concentrations and Comparisons With a Low-Molecular-Weight Heparin and With a Direct Thrombin InhibitorCirculation, 1998
- Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplastyAmerican Heart Journal, 1996
- Reactivation of Unstable Angina after the Discontinuation of HeparinNew England Journal of Medicine, 1992